JP2022516469A5 - - Google Patents
Info
- Publication number
- JP2022516469A5 JP2022516469A5 JP2021537781A JP2021537781A JP2022516469A5 JP 2022516469 A5 JP2022516469 A5 JP 2022516469A5 JP 2021537781 A JP2021537781 A JP 2021537781A JP 2021537781 A JP2021537781 A JP 2021537781A JP 2022516469 A5 JP2022516469 A5 JP 2022516469A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- nitrogen
- sulfur
- oxygen
- heteroatoms selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785733P | 2018-12-28 | 2018-12-28 | |
| US62/785,733 | 2018-12-28 | ||
| PCT/US2019/068648 WO2020139988A1 (en) | 2018-12-28 | 2019-12-27 | Compositions for inhibiting ubiquitin specific protease 1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516469A JP2022516469A (ja) | 2022-02-28 |
| JP2022516469A5 true JP2022516469A5 (cg-RX-API-DMAC7.html) | 2022-12-22 |
| JP7553450B2 JP7553450B2 (ja) | 2024-09-18 |
Family
ID=71126375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537781A Active JP7553450B2 (ja) | 2018-12-28 | 2019-12-27 | ユビキチン特異的プロテアーゼ1を阻害するための組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220073525A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3902802A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7553450B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113474346B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020139988A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114702495A (zh) | 2015-11-20 | 2022-07-05 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| EP4291559A1 (en) * | 2021-02-15 | 2023-12-20 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
| AU2022254062A1 (en) * | 2021-04-07 | 2023-10-12 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 1 (usp1) |
| US20240226107A1 (en) * | 2021-04-09 | 2024-07-11 | Simcere Zaiming Pharmaceutical Co., Ltd. | Ubiquitin-specific protease 1 (usp1) inhibitor |
| JP7746406B2 (ja) * | 2021-04-21 | 2025-09-30 | 長春金賽薬業有限責任公司 | イミダゾール含有縮合環系誘導体、その調製方法及びその医薬上の応用 |
| CN117412973B (zh) * | 2021-05-31 | 2026-07-17 | 上海瑛派药业有限公司 | 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用 |
| JP2024540921A (ja) * | 2021-10-19 | 2024-11-06 | 上海瑛派▲薬▼▲業▼有限公司 | Usp1阻害剤としての置換トリアゾロヘテロアリール化合物及びその応用 |
| KR20240117556A (ko) * | 2021-11-12 | 2024-08-01 | 인실리코 메디신 아이피 리미티드 | 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도 |
| US20250163049A1 (en) * | 2022-02-03 | 2025-05-22 | Exelixis, Inc. | Fused bicyclic heterocyclyl compounds as usp1 inhibitors |
| IL316542A (en) * | 2022-04-29 | 2024-12-01 | Jiangsu Yahong Meditech Co Ltd | Pyrimidine compound, method for its preparation, and pharmaceutical use thereof |
| US20240092779A1 (en) * | 2022-06-29 | 2024-03-21 | Zentaur Therapeutics Usa Inc. | Usp1 inhibitors and uses thereof |
| WO2024022519A1 (zh) * | 2022-07-28 | 2024-02-01 | 先声再明医药有限公司 | 杂环并嘧啶类化合物及其应用 |
| WO2024041634A1 (zh) * | 2022-08-26 | 2024-02-29 | 先声再明医药有限公司 | 三环类化合物及其应用 |
| WO2024078436A1 (zh) * | 2022-10-09 | 2024-04-18 | 海南先声再明医药股份有限公司 | 杂环并嘧啶类化合物、药物组合物及其应用 |
| EP4605391A1 (en) | 2022-10-21 | 2025-08-27 | Exelixis, Inc. | 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors |
| WO2024153250A1 (zh) * | 2023-01-20 | 2024-07-25 | 杭州英创医药科技有限公司 | 作为usp1抑制剂的化合物 |
| TW202509030A (zh) | 2023-05-08 | 2025-03-01 | 美商譚格醫療公司 | 化合物及使用方法 |
| WO2024233665A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| TW202446379A (zh) * | 2023-05-18 | 2024-12-01 | 香港商英矽智能科技知識產權有限公司 | 泛素特異性蛋白酶1(usp1)之小分子抑制劑及其用途 |
| EP4739397A1 (en) | 2023-07-06 | 2026-05-13 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| CN119930632B (zh) * | 2023-11-06 | 2025-11-18 | 中国医学科学院药物研究所 | 一种三并环类泛素特异性蛋白酶1抑制剂及其制备方法、用途和药物组合物 |
| CN119930633B (zh) * | 2023-11-06 | 2025-11-18 | 中国医学科学院药物研究所 | 一种吡咯并蝶啶酮类泛素特异性蛋白酶1抑制剂及其制备方法、用途和药物组合物 |
| AU2024378865A1 (en) | 2023-11-10 | 2026-06-25 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| WO2025151705A1 (en) | 2024-01-10 | 2025-07-17 | Vrise Therapeutics, Inc. | Novel inhibitors of dna damage repair pathway |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993012113A1 (en) * | 1991-12-17 | 1993-06-24 | The Upjohn Company | 3-SUBSTITUTED IMIDAZO (1,5-a) AND IMIDAZO (1,5-a)-TRIAZOLO (1,5-c) QUINOXALINES AND QUINAZOLINES WITH CNS ACTIVITY |
| EA201000046A1 (ru) * | 2007-06-21 | 2011-02-28 | Кара Терапеутикс, Инк. | Замещенные имидазогетероциклы |
| MX2011002581A (es) * | 2008-09-16 | 2011-04-07 | Proximagen Ltd | Compuestos nuevos i. |
| CN101824036A (zh) * | 2009-03-05 | 2010-09-08 | 上海恒瑞医药有限公司 | 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 |
| CN114702495A (zh) * | 2015-11-20 | 2022-07-05 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
-
2019
- 2019-12-27 WO PCT/US2019/068648 patent/WO2020139988A1/en not_active Ceased
- 2019-12-27 JP JP2021537781A patent/JP7553450B2/ja active Active
- 2019-12-27 EP EP19904923.0A patent/EP3902802A4/en not_active Withdrawn
- 2019-12-27 CN CN201980093028.5A patent/CN113474346B/zh active Active
- 2019-12-27 US US17/417,805 patent/US20220073525A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513534A5 (cg-RX-API-DMAC7.html) | ||
| JP2022501354A5 (cg-RX-API-DMAC7.html) | ||
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| RU2017111200A (ru) | Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака | |
| PE20230376A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
| JP2021532109A5 (cg-RX-API-DMAC7.html) | ||
| JP2019527718A5 (cg-RX-API-DMAC7.html) | ||
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos | |
| JP2016520063A5 (cg-RX-API-DMAC7.html) | ||
| JP2014511892A5 (cg-RX-API-DMAC7.html) | ||
| JP2015520769A5 (cg-RX-API-DMAC7.html) | ||
| JP2023553835A5 (cg-RX-API-DMAC7.html) | ||
| JP2016526024A5 (cg-RX-API-DMAC7.html) | ||
| JP2021535112A5 (cg-RX-API-DMAC7.html) | ||
| JP2012526728A5 (cg-RX-API-DMAC7.html) | ||
| JP2018527301A5 (ja) | アジリジン含有dnaアルキル化剤 | |
| AR048315A1 (es) | Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas. | |
| PE131699A1 (es) | Inhibidores de aminotiazol de cinasas dependientes de ciclina | |
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| AR043367A2 (es) | Derivados de benzofenona, composiciones farmaceuticas y procesos de preparacion. | |
| SI3024819T1 (en) | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B | |
| JP2009536620A5 (cg-RX-API-DMAC7.html) | ||
| JP2014511891A5 (cg-RX-API-DMAC7.html) | ||
| JP2022511477A5 (cg-RX-API-DMAC7.html) |